LILRB2 and neoplasm: PIR-B is a key regulator for maintaining the M2 phenotype of tumor-infiltrating MDSCs, and we demonstrated for the first time that blockade of LILRB2 induces differentiation MDSCs into the M1 type of macrophages, altering the tumor microenvironment towards anticancer responses (16).